PER-057-04已完成未知
A RANDOMIZED PHASE 3 ESSAY OF ALIMTA AND CISPLATINO VERSUS GEMZAR AND CISPLATINO IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC LUNG CANCER OF NON-SMALL CELLS.
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 0 至 0（—）
入选标准
- •Diagnosis of NSCLC Stage IIIB not amenable to curative treatment or Stage IV.
- •No prior chemotherapy for lung cancer.
- •Patients must have at least one uni-dimensionally measurable lesion.
- •Prior radiation therapy to less than 25% of bone marrow, whole pelvis not allowed. Radiation must be completed at least 4 weeks prior to study enrollment.
排除标准
- •Treatment with any drug within the last 30 days that has not received regulatory approval.
- •Serious cardiac condition.
- •Serious medical disorder in addition to NSCLC that would make it difficult for the patient to complete the study.
- •Inability or unwillingness to take folic acid or Vitamin B12 supplementation.
- •Presence of fluid retention that cannot be controlled by drainage.
研究者
相似试验
进行中（未招募）
1 期
Estudio fase 3, aleatorizado, doble ciego de siltuximab (anticuerpo monoclonal anti-IL-6) o placebo en combinación con VELCADE y dexametasona para el tratamiento de sujetos con mieloma múltiple en recaída o refractario.A Phase 3, Randomized, Double-blind Study of Siltuximab (Anti-IL-6 Monoclonal Antibody) or Placebo in Combination With VELCADE and Dexamethasone for the Treatment of Subjects With Relapsed or Refractory Multiple MyelomaEUCTR2009-017237-22-ESCentocor B.V.500
进行中（未招募）
不适用
ESTUDIO DE FASE III, ALEATORIZADO, CON DOBLE SIMULACIÓN Y CONTROLADO CON TRATAMIENTO ACTIVO, DE LA EFICACIA Y LA SEGURIDAD DE DOSIS INTRAVÍTREAS REPETIDAS DE VEGF TRAP¬ EYE EN SUJETOS CON EDEMA MACULAR DIABÉTICO// A randomized, double masked, active controlled, phase III study of the efficacy and safety of repeated doses of intravitreal VEGF Trap-Eye in subjects with diabetic macular edema.Edema macular diabético con afectación central//Diabetic macular edema with central involvementMedDRA version: 12.1Level: LLTClassification code 10057934Term: Diabetic macular edemaEUCTR2010-022364-12-ESBayer HealthCare AG375
进行中（未招募）
1 期
Estudio Fase III aleatorizado, multicéntrico, abierto de lapatinib, trastuzumab, la administración secuencial de ambos y la administración combinada de ambos como tratamiento adyuvante en pacientes con cáncer de mama HER2/ErbB2 positivo.Estudio ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation)ALTTO (Adjuvant Lapatinib and/or Trastuzumab Treatment Optimisation) studyA randomised, multi-centre, open-label, phase III study of adjuvant lapatinib, trastuzumab, their sequence and their combination in patients with HER2/ErbB2 positive primary breast cancer - ALTTOCancer de mama primario con sobreexpresión / amplificación de HER2 operable. Operable primary breast cancer with over expression / amplification of HER2.MedDRA version: 9.1Level: LLTClassification code 10006187Term: Breast cancerEUCTR2006-000562-36-ESGlaxoSmithKline S.A.8,381
进行中（未招募）
1 期
Ensayo aleatorizado de Fase III de gemcitabina/carboplatino con o sin BSI-201 (SAR240550) (un inhibidor de PARP1) en pacientes con cáncer de pulmón no microcítico (CPNM) epidermoide en estadío IV no tratado previamente__________________________________________________Randomized Phase 3 Trial of Gemcitabine/Carboplatin With or Without BSI-201 (SAR240550) (a PARP1 Inhibitor) in Patients with Previously Untreated Stage IV Squamous Non Small Cell Lung Cancer (NSCLC)cáncer de pulmón no microcítico_______________________________________Squamous Non Small Cell Lung CancerMedDRA version: 12.1Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2010-019255-22-ESBiPar Sciences, Inc.825
已完成
3 期
A Clinical trial to evaluate the safety and efficacy of dutogliptin in patients with type 2 diabetes mellitus (T2DM) who are receiving background therapy with glimepiride with or without metformiCTRI/2010/091/000078Forest Research Institute Inc650